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ABSTRACT
The purpose of this study is to review the cur-
rent literature on the use of hyaluronic acid
(HA) specifically applied to the treatment of
osteoarthritis (OA) secondary to primary
inflammatory rheumatic diseases. Osteoarthritis
should be carefully considered because it has
potentially devastating effects on health-related
quality of life. Locally injected HA seems to be
an effective treatment for OA but it is not clear
how to place this treatment in the context of
inflammatory rheumatic disorders. To retrieve
relevant articles, we conducted the search
through MEDLINE, EMBASE and Cochrane
Databases performing the PICO strategy. We
finally selected four randomized clinical trials
and six observational studies and grouped them
in accordance with its main objective within
three focuses: the clinical effect of HA therapy
in joints without any signs of inflammation, the
clinical effects of HA therapy in joints with
active synovitis, and the involvement and
changes of synovial fluid in the treatment of
secondary OA. Our qualitative analysis clearly
showed that the current literature is marked by
high levels of heterogeneity and therefore dif-
ficult to interpret. Therefore, our hypothesis
that viscosupplementation should be consid-
ered as a treatment for chronic moderate
symptomatic OA secondary to inflammatory
rheumatic diseases, and not for flares with joint
swelling, cannot be definitely supported. Well-
designed studies are necessary to definitively
clarify the range of application of intra-articular
HA injections in the treatment of inflammatory
rheumatic disorders.
Keywords: Hyaluronic acid; Osteoarthritis;
Qualitative synthesis; Rheumatic diseases;
Rheumatology; Systematic review; Viscosupple-
mentation
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Key Summary Points
Why carry out this study?
Osteoarthritis (OA) is the most frequent
comorbidity with self-reported
detrimental outcome in patients with
systemic rheumatic disorders.
Locally injected hyaluronic acid (HA)
seems to be an effective treatment for OA
comorbidity and despite its increasing use
in various conditions, doubts still exist
with regard to the most successful field of
application.
We conducted a systematic review aimed
at investigating the role of HA as local
treatment in OA secondary to chronic
inflammatory arthritis.
What was learned from the study?
Our review clearly showed that the current
literature on HA is affected by high
heterogeneity.
Well-designed studies are necessary to
definitively clarify the range of
application of viscosupplementation
therapy.
INTRODUCTION
Osteoarthritis (OA) is the most frequent
comorbidity with self-reported detrimental
outcome in patients with systemic rheumatic
disorders such as rheumatoid arthritis and other
inflammatory arthritides that progressively
affect joints. Osteoarthritis presence should be
carefully considered because it may alters pain
perception and functional status especially in
long-standing patients [1]. Inflammation plays
a central role in the development and progres-
sion of OA involving multiple mediators such as
interleukin-1 (IL-1), interleukin-6 (IL-6),
tumour necrosis factor alpha (TNFa) and met-
alloproteases that are responsible for
degradation of proteoglycans in the extracellu-
lar matrix and reduction in the molecular
weight and concentration of endogenous hya-
luronic acid (HA) [2]. HA is the major compo-
nent of synovial fluid and is responsible for its
viscoelastic properties. As a natural component
of cartilage, HA plays a crucial role in the
trophic status of the cartilage and in the regu-
lation of intra-articular environment.
Over the last decades, the introduction of
disease-modifying antirheumatic drugs
(DMARDs) and the acknowledgement of the
importance of early diagnosis, prompt treat-
ment and treat-to-target approach have radi-
cally changed the prognosis of these patients,
preventing cartilage damage and leading to a
notable decrease in total joint replacement
[3, 4]. Furthermore, locally injected HA seems to
be an effective treatment for OA comorbidity.
Indeed, results from several in vitro and in vivo
studies have indicated that exogenous HA can
decrease the production of pro-inflammatory
cytokines and stimulate the endogenous syn-
thesis of HA and extracellular matrix compo-
nents by synovial fibroblasts [5–9]. In all
inflammatory conditions of the joint, the
molecular weight of HA is reduced. Also, several
clinical studies have shown that intra-articular
HA relieves pain and improves function in
symptomatic OA joints [9–12] and that the
treatment has a positive global effect and is well
tolerated. Some studies, mainly focused on the
knee joint, have shown that repeated courses of
HA treatment are safe and associated with total
joint replacement delay for up to 3 years
[13, 14].
In a meta-analysis published in 2009 [15],
the authors summarised results from five trials
[16–20] aimed at evaluating the efficacy of intra-
articular HA injection in rheumatoid knees
(Table 1). The main extracted outcomes were
global pain and inflammation, global thera-
peutic efficacy and adverse effects. Risk ratio
was used as a measure of effect size. The therapy
was considered effective if it brought a moder-
ate to remarkable benefit according to a Likert
scale. The authors concluded that viscosupple-
mentation therapy is an effective and safe
alternative local treatment for the rheumatoid
knee when compared to placebo as they
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estimated a pooled overall efficacy of 1.64 in
favour of HA. The most common side effects
encountered were arthralgia and joint swelling.
Despite this body of evidence and the
increasing use of HA injections in primary
osteoarthritis, doubts still existwith regard to the
most successful field of application [21]. First of
all, viscosupplementation should be considered
as a treatment for chronic moderate symp-
tomaticOA, andnot forflareswith joint swelling,
and therefore some poor results may be due to
inappropriate use of HA injections. To better
understand theplace ofHA local treatment inOA
secondary to chronic inflammatory arthritis we
conducted a systematic review of the studies that
until now have accumulated evidence of safety
and efficacy/effectiveness of HA in relieving pain
and recovering joint functionality. As a result of
the high heterogeneity of the retrieved studies
(study design, treated joints, scheduling and
duration of the treatment, etc.), a qualitative
synthesis was performed.
METHODS
Search Strategy and Eligibility Criteria
The systematic review was conducted according
to the recommendations of PRISMA (Preferred
Reporting Items for Systematic Review and
Meta-Analysis) as conveyed in Moher’s
guidelines [22]. We performed an accurate
search of studies that evaluated patients suffer-
ing from OA secondary to primary inflamma-
tory arthritis undergoing intra-articular
injections of HA with the aim of assessing
treatment efficacy/effectiveness. To retrieve rel-
evant articles, we conducted the search through
MEDLINE (Pubmed), EMBASE and Cochrane
Database of Systematic Reviews. The search
terms entered were psoriatic arthritis, rheuma-
toid arthritis, ankylosing spondylitis, juvenile
idiopathic arthritis, spondyloarthropathies,
systemic lupus erythematosus, systemic sclero-
sis and Sjo¨gren’s syndrome as ‘‘population’’,
hyaluronic acid, hyaluronate, sodium hyalur-
onate, hyaluronate injection(s), viscosupple-
mentation as ‘‘intervention’’ and Lequesne
index, VAS, WOMAC, pain, SF-36, HAQ, effec-
tiveness, efficacy, satisfactory as ‘‘outcome’’. All
relevant index and natural language terms were
tailored for all databases searched. In addition,
further relevant references were manually sear-
ched if needed. In particular, the latest meta-
analysis and systematic reviews were addition-
ally screened for any other relevant articles that
could have been missed using the literature
search strategy. Duplicate results were removed
and the first screening process was done con-
sidering the title and abstract only. The inclu-
sion/exclusion criteria used to determine which
research should be retrieved are included in
Table 2. A second selection was performed by
Table 1 Results of the meta-analysis by Saito and Kotake [15]
References Patients, n RRa of pain [95% CI] RRa of inflammation
[95% CI]
RRa of efficacy
[95% CI]
Tanaka et al. [16] 175 1.19 [0.96–1.47] 1.40 [1.07–1.83] 1.29 [1.07–1.55]
Tanaka et al. [17] 203 1.83 [1.44–2.32] 1.78 [1.37–2.32] 1.76 [1.40–2.21]
Goto [18] 20 2.00 [0.68–5.85] 1.60 [0.80–3.20] 2.12 [1.06–4.26]
Matuno [19] 26 2.75 [1.18–6.42] 3.50 [0.89–13.78] 4.00 [1.46–10.93]
Komatubara et al. [20]b 286 – – 1.10 [0.95–1.27]
Pooled RR 1.64 [1.14–2.35] 1.61 [1.34–1.92] 1.64 [1.14–2.35]
a A value of risk ratio (RR) greater than 1 indicates that the observed results favours HA injections as compared to placebo
b The study by Komatubara et al. was excluded from the estimation of RR of pain and inflammation because the authors
used a different outcome measure with respect to the other included studies
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fully reading the manuscript of the previously
selected references. The review selection was
independently performed by two reviewers
(ODL and FP) whereas the discrepancies were
solved by discussion with a third reviewer (AM)
involved in case of no consensus could be
achieved. The information about the numbers
of articles generated by using search terms, the
numbers of articles ruled out after the first
screening and the reason for any excluded arti-
cle were inserted in a PRISMA flow chart.
The last part of this work focused on a critical
review of the selected literature. This article is
based on previously conducted studies and does
not contain any studies with humanparticipants
or animals performed by any of the authors.
Quality Assessment
The articles that met all inclusion criteria were
evaluated in relation to methodological quality.
The Quality Assessment Tool for before–after
(pre–post) studies with no control group and
cross-sectional studies (https://www.nhlbi.nih.
gov/health-topics/study-quality-assessment-tools)
was used as appraisal tool for evaluating the
quality of observational studies, whereas each
randomized controlled trial (RCT) was scored by
the Jadad scale [23].
RESULTS
Systematic Review Process
Articles were retrieved from the databases on
September 24, 2019. Our search yielded 122
records, 73 from EMBASE, 18 from MEDLINE
and 31 from Cochrane Library. After removal of
duplicates (n = 15), 107 titles and abstracts were
assessed according to inclusion/exclusion crite-
ria. From this first screening, 11 potentially eli-
gible articles underwent a full reading and only
one text was removed as the included infor-
mation was not relevant for answering our
research question. It was not possible to include
the five articles from the meta-analysis per-
formed by Saito and Kotake [15] as they were all
published in Japanese. Therefore, the qualita-
tive synthesis was based on ten original articles
(Fig. 1).
Overall Characteristics of Selected Studies
The main characteristics of the articles are
shown in Table 3. They included four RCT
[24–27] and six observational studies [28–34]
(five pre–post study with no control group and
one cross-sectional design). In all studies,
patients were affected by RA. In general, these
studies differed in the primary endpoint, HA
preparation and scheduling, injection site and
outcome measures. Therefore, we grouped each
study in accordance with its main objective
within three main focuses: the clinical effect of
HA therapy in joints without any signs of
inflammation, the clinical effects of HA therapy
in joints with active synovitis, and the
involvement and changes of synovial fluid in
the treatment of secondary OA (impact of the
arthrocentesis and biochemical effects of
Table 2 Inclusion/exclusion criteria for screening titles
and abstracts
Inclusion criteria Exclusion criteria
Full-text original articles
English language
Articles concerning OA
secondary to the following
diseases: psoriatic arthritis,
rheumatoid arthritis,
ankylosing spondylitis,
juvenile idiopathic
arthritis,
spondyloarthropathies,
systemic lupus
erythematosus, systemic
sclerosis and Sjo¨gren’s
syndrome
Providing relevant
information (e.g. response
rate or other measures of
effectiveness)
Study design: any
Abstract-only, letters to
editor, reviews, case
reports
Papers that do not deal
with intra-articular
injection in patients with
osteoarthritis secondary
to inflammatory
rheumatic diseases
When multiple articles
were based on the same
study population, we
included only the most
complete (or recent) one
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exogenous HA in synovial fluid). As the inclu-
ded studies themselves have not clearly defined
or clinically described joints with or without
inflammation, we included the manuscripts in
the group of joints with active synovitis when
the authors did not specifically exclude patients
with active disease. Indeed, in these cases the
averaged values of the disease activity score-28
(DAS28) indicated a moderate to severe active
rheumatic disease. On the other hand, we
included the manuscript by Chou et al. [30] into
the group of secondary osteoarthritis without
any sign of inflammation as the authors stated
that patients with RA were excluded in case of
significantly inflamed osteoarthritic knees.
Overall, among the retrieved RCTs, only
Tanaka [27] and Kopp [25] achieved a poorer
rating score (Jadad score = 3) because the
randomization method was not declared,
whereas the observational studies fell within
fair and good categories.
Qualitative Synthesis
Clinical Effects of Intra-Articular HA
Administration in Joints Affected by Secondary
Osteoarthritis Without Any Sign
of Inflammation
Only one study [30] specifically covered this
topic. However, it was not possible to com-
pletely rule out the inflammatory condition as
patients with RA were excluded in case of sig-
nificantly but only radiologically verified
inflamed osteoarthritis of the knee. Briefly, HA
intra-articular injections allowed an overall
significant and quick improvement (after
Fig. 1 Flow chart showing the number of records identified and removed at each stage of the review, according to the
PRISMA statement
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5 weeks) of patients’ conditions in terms of
pain, stiffness and physical function. Notewor-
thy, the authors observed a score reduction
from baseline of about 50% and the effects of
the local therapy were still present 1 month
after the last HA injection. Nevertheless, these
results are affected by a fair risk of bias because
of the small sample size (n = 20) and the lack of
a control group.
Clinical Effects of Intra-Articular
Administration of HA in Joints with Active
Synovitis
Five studies were included in this topic, two
RCTs [24, 25], two uncontrolled longitudinal
studies [32, 33] and one cross-sectional study
[31]. Overall, 370 HA injections within eight
different joints (shoulder, knee, ankle, foot,
elbow, wrist, fingers and toes) were evaluated.
The evaluated outcomes varied from generic
scales of pain assessment such as VAS to more
specific measures of joint function such as foot
function index. Overall, each study resulted in
improvements in joint function and pain when
compared with baseline conditions, whereas the
differences between HA and corticosteroid
injections were not always evident. In the
medical survey approach by Saito et al. [31], the
authors concluded that, irrespective of joint,
both HA and corticosteroids were almost
equally effective in treating RA, where effec-
tiveness was measured in terms of satisfactory
rate. Similar conclusions were reached also in
the RCT including patients with dysfunction of
the temporomandibular joint (TMJ) [25], where
HA and glucocorticoids had similar beneficial
effects on both subjective and clinical signs of
TMJ arthritis with a better performance of the
latter in reducing lateral and posterior tender-
ness to palpation.
When compared to lidocaine [24], HA vis-
cosupplementation appeared more effective in
quickly reducing pain and disability with regard
to ankles and feet affected by RA. No anti-in-
flammatory effect was seen because of the lack
of reduction in synovial hypervascularization.
On the other hand, Isdale and colleagues
[33] observed only a very little benefit of HA in
the treatment of the knee joint of ten patients
with RA compared to the group affected byT
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primary OA, but the conclusions referred only
to short-term effects.
Lastly, the study by Cheng and Tan [32]
differed from the others as HA effectiveness was
tested on patients with elderly-onset RA. Briefly,
the authors observed longer-lasting effects,
from 2 months to 3 years, confirming the posi-
tive trend of HA injections in reducing pain and
disability.
Exogeneous Hyaluronan and Synovial Fluid
Biodynamic Performance Regarding this
topic, we included three studies [26, 29, 34]. In
all studies except that by Matsuno et al. [26] the
treatment was preceded by synovial fluid aspi-
ration. A total of 46 patients and 47 knees were
assessed before and after HA injection. Changes
in some or all biochemical properties of
rheumatoid synovial fluid (i.e. endogenous HA
concentration, viscosity, stringency and syn-
ovial fluid volume) after intra-articular injection
of HA were observed, whereas systemic inflam-
matory parameters (erythrocyte sedimentation
rate and C-reactive protein) did not show any
statistically significant improvement. A local
significant reduction of the levels of
prostaglandin E2 and chondroitin sulfate may
be partly attributed to the improvement of
synovitis parameters in the studies by Matsuno
[26] and Goto [29]. The pain scores significantly
decreased in all cases. Radiographical examina-
tion did not show any statistically significant
improvement. Of note, only one study [26] was
designed to have a control group (1% versus
0.01% HA) randomly assigned to treatment.
Impact of Arthrocentesis The study by Tanaka
[27] specifically focused on the effect of com-
plete aspiration of the synovial fluid from the
knee joint before the injection of high molec-
ular weight hyaluronan. Patients suffering from
RA and with symptoms of knee arthritis
including effusion were enrolled. The study
protocol envisaged a second group of patients
in which the synovial fluid aspiration was not
performed. The strengths of this study are the
random allocation of patients to arthrocentesis
or no arthrocentesis, the long-term evaluation
(6 months of follow-up) and the quite large size
of the sample (118 patients, 161 knees). The
authors observed a higher prevalence of no
relapses in the arthrocentesis group (66% versus
40% at 180 days). Predicting responders are
duration of the knee arthritis (OR [95% CI] 1.07
[1.02–1.12]), C-reactive protein (OR [95% CI]
2.58 [1.11–5.95]) and radiological grade (OR
[95% CI] 3.59 [1.53–8.39]) as assessed by the
Larsen method.
Adverse Events
There were no adverse effects during the treat-
ment. The only adverse event occurred after
four intra-articular injections of HA and was due
to the aggravation of systemic rheumatoid
inflammation. Therefore, it was probably not
related to the local treatment.
DISCUSSION
In this study we performed a systematic review
of the literature concerning the application of
viscosupplementation in the treatment of OA in
inflammatory autoimmune rheumatic disorders
with the aim of investigating the current evi-
dence of its efficacy/effectiveness.
The randomized and non-randomized stud-
ies carried out in this field are very heteroge-
neous and affected by some important biases
(inadequate sample size; observational studies
missing control groups; studies were conducted
almost exclusively in Asia; subjects with differ-
ent radiological degrees were not always inde-
pendently analysed; outcomes were not always
adequate, etc.). Furthermore, all the included
manuscripts are exclusively restricted to RA and
published many years ago, implicating that
inclusion criteria and drug formulations could
be changed over time. Therefore, the main
consideration that arises from our review is the
need to better clarify the correct scope of vis-
cosupplementation in the treatment of rheu-
matic inflammatory disorders in a modern and
well-designed setting.
The rationale of HA therapy in patients suf-
fering from inflammatory rheumatic diseases
such as RA derives from the results of several
in vitro and in vivo models experiments [35]. In
a hypothetical biochemical pathway,
Adv Ther
inflammatory conditions lead to the depoly-
merization of native HA into small fragments
that may produce a range of proinflammatory
responses. It is speculated that these small pie-
ces of different sizes directly bind Toll-like
receptor 4 (TLR-4) and CD44 inducing activa-
tion of several pathways that finally trigger NF-
jB activation and its translocation to the
nucleus, then perpetuating the tissue injury
through the transcription of several detrimental
intermediates. The injected HA would increase
the local concentration of the synovial
polysaccharide and displace the degraded HA
from these receptors with consequent inhibi-
tion of TLR4 and CD44 activity and blocking of
inflammation, finally allowing tissue repair. In
this regard, several experimental animal models
of OA in RA have elucidated the molecular and
pathophysiological mechanisms of cartilage
inflammation/degeneration and have demon-
strated the positive effect of exogenous HA on
the preservation of joint cartilage. In spite of
this, in our systematic review we observed that
the current literature on clinical application of
viscosupplementation did not offer the same
univocal message. In part, this heterogeneity
can be explained because, in the majority of the
cases, the therapy has been applied in patients
with active synovitis. This is a critical point
because intra-articular injections of both HA
and corticosteroids are symptom-modifying
agents and do not prevent or slow the disease
progression [36]. On the other hand, only one
study investigated the mechanical properties of
HA but it did not offer enough evidence, miss-
ing a control group and including a very small
sample size.
Furthermore, another doubtful conclusion
raised from this systematic review was the lack
of a substantial difference between corticos-
teroid and hyaluronan injection. Only two
studies compared the value of these treatments,
the survey by Saito et al. [31] and the manu-
script by Kopp et al. [25] that concerned
patients with RA involving the TMJ. However,
both studies displayed crucial limitations: the
former measured the effectiveness using sub-
jective patient-reported experience, whereas the
latter was affected by confounding factors
influencing the outcome of treatments.
Noteworthy, although the exact mechanism of
action of both agents remains unknown, it is
widely recognized that the viscosupplementa-
tion has a more favourable long-term profile
than repeated steroids [36].
In summary, as many unresolved issues
encompass the use of HA in musculoskeletal
disorders, well-design studies are required to
determine its most appropriate position in the
framework for clinical practice.
CONCLUSION
This review clearly shows that the results of the
current literature on HA utility in the treatment
of secondary OA are based on old and hetero-
geneous studies, and therefore difficult to
interpret. Well-designed studies are necessary to
definitively clarify the range of application of
viscosupplementation therapy.
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